• Skip to primary navigation
  • Skip to content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • Contact

Jerini AG

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • Contact
jerini

Jerini AG

Exit: 2008
Visit Website
  • Germany
  • Bradikinin B2 receptor based drugs for angioedema and severe burn, drugs for ophthalmic disease indications
  • Investment Period: 7 years
  • 2005 IPO on the Frankfurt Stock Exchange
  • 2008 Strategic Acquisition by Shire Limited

TVM Capital Partner Hubert Birner served on the Supervisory Board and was instrumental in M&A negotiation prior to the acquisition. He served as Vice Chairman of the Board throughout all the years of investment and led the company through several challenging situations include a senior management change over.

  • in

Copyright © 2019 · TVM Capital Life Science Venture Capital · Privacy Policy · Contact

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkNoRead more
Revoke Cookies